<DOC>
	<DOCNO>NCT01195870</DOCNO>
	<brief_summary>Multiple sclerosis ( MS ) chronic disease cause inflammation destruction nerve within brain spinal cord . This disease one common cause disability young adult . A `` relapse '' phenomenon occur acute attack disability result acute attack nervous system . There usually degree recovery relapse . Rebif license United Kingdom treatment relapse MS give 3 time week injection skin . The RebiSmart device new injection device develop help patient inject Rebif treatment . Currently , treatment MS injectable require long term patient commitment . Patient compliance treatment important therapy work effectively decrease risk relapse episode . Using device make easy patient inject may potentially improve compliance treatment therefore potentially impact number relapse patient experience . The RebiSmart device develop patient inject conveniently comfort . The device allow patient control certain parameter needle depth , needle speed , injection time etc , also extra feature design ease injection process , dose history calendar onâˆ’screen injection guide . The aim study determine percentage patient like use RebiSmart device find `` easy '' `` easy '' use . The study also determine device feature useful patient .</brief_summary>
	<brief_title>Assessment Patient Use New Device : RebiSmart</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Have relapse remit multiple sclerosis Between 18 65 year old inclusive Have prescribe Rebif first time yet start treatment Rebismart chosen device Be review MS nurse Having give write informed consent participate study Injections Rebif give someone patient Patients unable use Rebismart device due visual physical impairment Patients unwilling give inform consent Contraindications Rebif define Summary Product Characteristics ( SPC ) . Allergy antipyretic analgesic advise prophylaxis flulike symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Rebif</keyword>
	<keyword>Interferon beta-1a</keyword>
</DOC>